ADMA Biologics soared as FDA approved its new immunoglobulin production process, promising a 20% increase in output. This advancement in Bivigam and Asceniv products aims to boost revenue and earnings, offering virus-blocking antibodies to those with immunodeficiency.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing